BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 21646683)

  • 21. [JAK2 exon 12 mutations in patients with Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms].
    Wang JY; Ai XF; Xu JQ; Li QH; Xu ZF; Qin TJ; Zang Y; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Sep; 33(9):705-9. PubMed ID: 23336221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
    Tibes R; Mesa RA
    Leuk Lymphoma; 2011 Jul; 52(7):1178-87. PubMed ID: 21599574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic potential of JAK2 inhibitors.
    Verstovsek S
    Hematology Am Soc Hematol Educ Program; 2009; ():636-42. PubMed ID: 20008249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
    Tefferi A
    Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
    Kirabo A; Park SO; Majumder A; Gali M; Reinhard MK; Wamsley HL; Zhao ZJ; Cogle CR; Bisht KS; Keserü GM; Sayeski PP
    Neoplasia; 2011 Nov; 13(11):1058-68. PubMed ID: 22131881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular characterization of chronic myeloproliferative neoplasias in México.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Ortiz-López R; Rivas-Llamas R; Gómez-Almaguer D; Ruiz-Delgado GJ
    Hematology; 2009 Oct; 14(5):261-5. PubMed ID: 19843380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
    Pomicter AD; Eiring AM; Senina AV; Zabriskie MS; Marvin JE; Prchal JT; O'Hare T; Deininger MW
    Exp Hematol; 2015 Jul; 43(7):537-45.e1-11. PubMed ID: 25912019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
    Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
    Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.
    Bhagwat N; Koppikar P; Keller M; Marubayashi S; Shank K; Rampal R; Qi J; Kleppe M; Patel HJ; Shah SK; Taldone T; Bradner JE; Chiosis G; Levine RL
    Blood; 2014 Mar; 123(13):2075-83. PubMed ID: 24470592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloproliferative and lymphoproliferative disorders: State of the art.
    Rumi E; Baratè C; Benevolo G; Maffioli M; Ricco A; Sant'Antonio E
    Hematol Oncol; 2020 Apr; 38(2):121-128. PubMed ID: 31833567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
    Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
    Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Not Available].
    Soret J; Kiladjian JJ
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting myeloproliferative neoplasms with JAK inhibitors.
    Pardanani A; Tefferi A
    Curr Opin Hematol; 2011 Mar; 18(2):105-10. PubMed ID: 21245760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.
    Pardanani A; Lasho TL; Finke CM; Mai M; McClure RF; Tefferi A
    Leukemia; 2010 Jun; 24(6):1146-51. PubMed ID: 20410924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Cancer; 2012 Feb; 118(4):870-7. PubMed ID: 21766300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.